Eficacitatea preparatului vezicare r (Solifenacin) in tratamentul incontinenţei urinare prin imperiozitate la femei

Tuchila Viorel; Banov Pavel; Ghicavîi Vitalie; Ceban Emil; Oprea Andrei; Dumbrăveanu Ion; Tănase Adrian

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

281

Ultima descărcare din IBN:
2023-01-17 02:53

SM ISO690:2012

TUCHILA, Viorel, BANOV, Pavel, GHICAVÎI, Vitalie, CEBAN, Emil, OPREA, Andrei, DUMBRĂVEANU, Ion, TĂNASE, Adrian. Eficacitatea preparatului vezicare r (Solifenacin) in tratamentul incontinenţei urinare prin imperiozitate la femei. In: Arta Medica , 2011, nr. 2S(45), pp. 165-167. ISSN 1810-1852.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Arta Medica

Numărul 2S(45) / 2011 / ISSN 1810-1852 /ISSNe 1810-1879

Eficacitatea preparatului vezicare r (Solifenacin) in tratamentul incontinenţei urinare prin imperiozitate la femei

Vezicare® (Solifenacin) efficiency in the treatment of urge urinary incontinence in women

Pag. 165-167

Tuchila Viorel¹, Banov Pavel², Ghicavîi Vitalie², Ceban Emil², Oprea Andrei², Dumbrăveanu Ion², Tănase Adrian²

¹ IMSP Spitalul Clinic Republican „Timofei Moșneaga”,
² Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“

Disponibil în IBN: 28 martie 2022

Descarcă PDF

Rezumat

The imperative incontinence of urine at women is one of the actual problems in modern uroginecology. Research objective is to define clinical efficiency of a medical product Solifenacin (Vezicare®) in conservative treatment of imperative incontinence of urine in women. The treatment full effect was observed in 12 patients (60 %), partial – at 8 patients (40 %), absence of effect from treatment has not been noted.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-152697</cfResPublId>
<cfResPublDate>2011-08-01</cfResPublDate>
<cfVol>45</cfVol>
<cfIssue>2S</cfIssue>
<cfStartPage>165</cfStartPage>
<cfISSN>1810-1852</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/152697</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Eficacitatea preparatului vezicare r (Solifenacin) in tratamentul incontinenţei urinare prin imperiozitate la femei</cfTitle>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>The imperative incontinence of urine at women is one of the actual problems in modern uroginecology. Research objective is to define clinical efficiency of a medical product Solifenacin (Vezicare&reg;) in conservative treatment of imperative incontinence of urine in women. The treatment full effect was observed in 12 patients (60 %), partial &ndash; at 8 patients (40 %), absence of effect from treatment has not been noted.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-19513</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-29875</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11096</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10919</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11453</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11064</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11795</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-19513</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-19513-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
<cfFamilyNames>Tuchila</cfFamilyNames>
<cfFirstNames>Viorel</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-29875</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-29875-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
<cfFamilyNames>Banov</cfFamilyNames>
<cfFirstNames>Pavel</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11096</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11096-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
<cfFamilyNames>Ghicavîi</cfFamilyNames>
<cfFirstNames>Vitalie</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10919</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10919-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
<cfFamilyNames>Ceban</cfFamilyNames>
<cfFirstNames>Emil</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11453</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11453-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
<cfFamilyNames>Oprea</cfFamilyNames>
<cfFirstNames>Andrei</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11064</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11064-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
<cfFamilyNames>Думбрэвяну</cfFamilyNames>
<cfFirstNames>И.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11795</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11795-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2011-08-01T24:00:00</cfStartDate>
<cfFamilyNames>Тэнасе</cfFamilyNames>
<cfFirstNames>Адриан</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>